Compound library / Research / Investigational
Long-acting somatostatin analogue that suppresses GH, IGF-1, glucagon, and insulin secretion; FDA-approved for acromegaly and carcinoid tumors, but explored in biohacking circles for IGF-1 modulation and cancer-adjacent protocols.
| Category | Research / Investigational |
|---|---|
| Typical route | Subcutaneous |
| Half-life | ~1.7-1.9 hours (immediate-release); LAR depot effective ~4 weeks |
| Common dose range | 50-200 mcg SC 3x/day (immediate-release); 10-30 mg/month IM (LAR) |
| Typical cycle length | Per clinical indication; not established for non-clinical use |
BioHack Track models Octreotide (Sandostatin) at a half-life of 1.8 hours, so every dose you log is decayed against that curve and the app shows what is still circulating — not just what you typed.
Immediate-release: supplied in pre-filled syringes. LAR: requires reconstitution with provided diluent at clinic.
Refrigerate.
Prescription medication. Suppresses multiple hormones including thyroid and GI hormones, causing GI side effects, gallstones, and blood glucose dysregulation. Not for self-administration outside clinical guidance.
Track Octreotide (Sandostatin) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for Octreotide (Sandostatin) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.